Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · IEX Real-Time Price · USD
3.090
-0.130 (-4.04%)
At close: Jul 19, 2024, 4:30 PM
3.220
+0.130 (4.21%)
Pre-market: Jul 22, 2024, 9:11 AM EDT
Sagimet Biosciences Employees
As of December 31, 2023, Sagimet Biosciences had 10 total employees, including 8 full-time and 2 part-time employees. The number of employees did not change compared to the previous year.
Employees
10
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$200,000
Profits / Employee
-$2,791,800
Market Cap
98.61M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 10 | 0 | - |
Dec 31, 2022 | 10 | 3 | 42.86% |
Dec 31, 2020 | 7 | - | - |
Related Stocks
Company Name | Employees |
---|---|
So-Young International | 1,357 |
Xtant Medical Holdings | 215 |
Adicet Bio | 143 |
Omega Therapeutics | 94 |
Aclaris Therapeutics | 91 |
VistaGen Therapeutics | 40 |
Sensus Healthcare | 35 |
Cardiff Oncology | 32 |
SGMT News
- 6 weeks ago - Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat - GlobeNewsWire
- 6 weeks ago - Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024 - GlobeNewsWire
- 2 months ago - Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024 - GlobeNewsWire
- 2 months ago - Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 2 months ago - Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024 - GlobeNewsWire
- 2 months ago - Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer - GlobeNewsWire
- 3 months ago - Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024 - GlobeNewsWire
- 4 months ago - Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat - GlobeNewsWire